UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported)

February 2, 2006

 

MedImmune, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation or organization)

0-19131

(Commission File No.)

52-1555759

(I.R.S. Employer Identification No.)

 

One MedImmune Way, Gaithersburg, MD 20878

(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code (301) 398-0000

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

 

Item 2.02.

Results of Operations and Financial Condition.

On February 2, 2006, MedImmune, Inc. (the “Company”) issued a press release announcing the Company’s results as of and for the fourth quarter and fiscal year ended December 31, 2005, and will conduct a previously announced, publicly available conference call to discuss those results. A copy of the Company’s press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is hereby furnished in its entirety pursuant to Item 2.02.

 

Item 9.01.

Financial Statements and Exhibits.

 

(d)

Exhibits.

 

See the attached Exhibit Index.

 

 

 

 


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

MedImmune, Inc.

 

 

Date: February 2, 2006

By:

/s/ Atul Saran

Atul Saran

Senior Director, Legal Affairs

and Assistant Secretary

 

 

 


 

EXHIBIT INDEX

 

 

Exhibit No.

Description

 

99.1

Press Release dated February 2, 2006, titled “MedImmune Reports 2005 Financial Results”